Friday, 30 November 2012

Assay provides fluorescence polarization-based detection to help advance drug research on epigenetic targets

Cisbio Bioassays, developer of products, technologies and services used for assay development and drug screening and for in vitro diagnostics, has announced that it has signed a global distribution agreement with BellBrook Labs, provider of high throughput screening tools, for BellBrook Labs’ Transcreener EPIGEN Methyltransferase assay.

Under the terms of the agreement, Cisbio Bioassays will offer this universal, fluorescence polarization-based tool for drug discovery studies in the growing field of epigenetics to pharmaceutical and biotechnology researchers in Europe, the United States and Asia through its network of sales teams.

Transcreener EPIGEN Methyltransferase is a universal detection method based on Transcreener AMP/GMP assay technology, a proprietary technology platform developed and patented by BellBrook Labs. 

The assay involves coupling enzymes that detect the product of methyltransferase reactions, crucial targets in epigenetic studies. Its homogeneous format enables detection at low substrate concentrations and offers researchers the sensitivity needed to detect enzyme function, as well as the technical aspects required for their industrial high throughput screening. In particular, the assay avoids difficulties in detecting specifically methylated products that are generated by methyltransferases and can be used with any kind of substrate, including complex and multi-protein. 

This distribution agreement marks the second collaboration between Cisbio Bioassays and BellBrook Labs. In January 2008, Cisbio Bioassays launched HTRF Transcreener ADP, a universal and flexible assay for the high-throughput screening and profiling of kinases based on proprietary technologies from both companies.